28 completed, 4 recruiting, 2 active not recruiting, 2 terminated. 40 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 40 | Completed 28, Recruiting 4, Active not recruiting 2, Terminated 2, Unknown 2, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 9 | Completed 7, Active not recruiting 1, Recruiting 1 |
Follow Hypertriglyceridemia: new trials by email Literature Review of Hypertriglyceridemia trials Research Report on Hypertriglyceridemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First-in-Human Study of ISH0688: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics ISH0688 for injection, Placebo - Healthy Subjects, Hyperlipidemia, Hypertriglyceridemia | Phase 1 | Not yet recruiting | SUNHO（China）BioPharmaceutical CO., Ltd. | 104 | 2026-03-01 | 2026-04-01 |
| a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia JMT202 injection, Placebo - Hypertriglyceridemia | Phase 1 / Phase 2 | Recruiting | Shanghai JMT-Bio Inc. | 48 | 2025-09-09 | 2025-12-30 |
| Single-ascending Dose Study of Kylo-12 in Healthy Subjects Kylo-12, Placebo - Hypertriglyceridemia | Phase 1 | Active not recruiting | Kylonova (Xiamen) Biopharma co., LTD. | 50 | 2025-03-12 | 2026-03-16 |
| Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia VERVE-201 - Hypercholesterolemia, Hypertriglyceridemia | Phase 1 | Recruiting | Verve Therapeutics, Inc. | 132 | 2024-10-30 | 2026-10-23 |
| Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects RN0361 - Hypertriglyceridemia, Familial Chylomicronemia Syndrome | Phase 1 / Phase 2 | Active not recruiting | Ikaria Bioscience Pty Ltd | 108 | 2024-09-30 | 2025-12-30 |
| Safety Evaluation of Gene Therapy Drug in the Treatment of Primary Hypertriglyceridemic Patients With Recurrent Pancreatitis GC304 - Hypertriglyceridemia, Familial | Phase 1 | Recruiting | GeneCradle Inc | 7 | 2024-09-20 | 2025-07-03 |
| A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias CTX310 - Cardiovascular, Metabolic Disease | Phase 1 | Recruiting | CRISPR Therapeutics AG | 90 | 2024-06-21 | 2026-09-18 |
| Study of MAR001 in Adults With Metabolic Dysfunction MAR001, Placebo - Hypertriglyceridemia | Phase 1 / Phase 2 | Completed | Marea Therapeutics | 55 | 2023-07-22 | 2025-11-13 |
| A VSA003 Phase 1 Study in Chinese Adult Healthy Volunteers VSA003, 0.9% NaCl - Dyslipidemias, Familial Hypercholesterolemia | Phase 1 | Completed | Visirna Therapeutics HK Limited | 36 | 2023-06-01 | 2025-09-12 |
| A Study of LY3875383 in Healthy Participants and Participants With Hypertriglyceridemia LY3875383, Placebo - Hypertriglyceridemia | Phase 1 | Terminated | Eli Lilly and Company | 41 | 2022-11-14 | 2025-06-04 |
| Study to Evaluate the Safety and PK of UI018 administration of UI018, co-administration of UIC201806 and UIC201602 - Hyperlipemia, Mixed | Phase 1 | Unknown | Korea United Pharm. Inc. | 44 | 2021-09-06 | 2021-12-21 |
| A Phase 1, First Time in Humans Study of NST-1024 NST-1024, Placebo - Hypertriglyceridemia | Phase 1 | Completed | NorthSea Therapeutics B.V. | 96 | 2020-10-27 | 2022-12-02 |
| A First in Human Study of STT-5058, an Antibody That Binds ApoC3 STT-5058, Placebo - Hypertriglyceridemia | Phase 1 | Terminated | Staten Biotechnology BV | 93 | 2020-05-26 | 2023-01-23 |
| Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS) ARO-APOC3, sterile normal saline (0.9% NaCl) - Hypertriglyceridemia, Familial Chylomicronemia | Phase 1 | Completed | Arrowhead Pharmaceuticals | 112 | 2019-03-08 | 2025-12-24 |
| Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients ARO-ANG3, sterile normal saline (0.9% NaCl) - Dyslipidemias, Familial Hypercholesterolemia | Phase 1 | Completed | Arrowhead Pharmaceuticals | 93 | 2019-01-07 | 2025-12-24 |
| Study of Gemcabene in Adults With FPLD 300mg Gemcabene, 600mg Gemcabene - Familial Partial Lipodystrophy, Hypertriglyceridemia | Phase 1 / Phase 2 | Completed | Elif Oral | 5 | 2018-03-13 | 2020-08-17 |
| Safety Study of LLF580 in Obese Volunteers LLF580, Placebo - Obesity | Phase 1 | Completed | Novartis Pharmaceuticals | 61 | 2018-02-26 | 2021-10-12 |
| Phase I Drug-drug Interaction of Omega-3 and Atorvastatin Omacor, Pritor, Omacor + Pritor - Hyperlipidemia, Hypertriglyceridemia | Phase 1 | Unknown | DongKoo Bio & Pharma | 48 | 2018-02-01 | 2018-02-22 |
| Effects of Two Herbal Dietary Supplements on Lipid Metabolism in Moderate Hypercholesterolemia and Hypertriglyceridemia VAL070-A, VAL070-B, Placebo - Hypercholesterolemia, Hypertriglyceridemia | Phase 1 / Phase 2 | Completed | Valbiotis | 40 | 2017-01-01 | 2018-07-05 |
| Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides APOC-III-L-Rx, Placebo Comparator - Elevated Triglycerides (TG) | Phase 1 | Completed | Ionis Pharmaceuticals, Inc. | 56 | 2016-09-01 | 2018-05-22 |
Showing 20 of 40. Sign in to see all of them.
Dyslipidemias (5) · Hypercholesterolemia (4) · Hyperlipoproteinemia Type II (4) · Hyperlipidemias (3) · Cardiovascular Diseases (2) · Hyperlipoproteinemia Type I (2) · Hyperlipoproteinemia Type V (2) · Lipid Metabolism Disorders (2) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Familial hyperchylomicronemia syndrome (1) · Fatty Liver (1) · Homozygous Familial Hypercholesterolemia (1) · Hyperlipoproteinemia Type IV (1)
Nutritional and Metabolic Diseases (40) · Metabolic Diseases (39) · Lipid Metabolism Disorders (38) · Hyperlipidemias (37) · Dyslipidemias (35) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10) · Genetic Diseases, Inborn (10) · Lipid Metabolism, Inborn Errors (10) · Metabolism, Inborn Errors (9) · Hyperlipoproteinemias (8) · Endocrine System Diseases (2) · Glucose Metabolism Disorders (2) · Body Weight (1) · Diabetes Mellitus (1)
Omacor (4) · eicosapentaenoic acid ethyl ester (3) · Aspirin (1) · Fatty Acids, Omega-3 (1) · Fenofibrate (1) · Fish Oils (1) · Fructose (1) · Gemfibrozil (1) · Glucose (1) · IONIS-ANGPTL3-LRx (1) · Injections (1) · Lopinavir (1) · MAT9001 (1) · Maraviroc (1) · Metformin (1)
AstraZeneca (4) · Essentialis, Inc. (3) · Arrowhead Pharmaceuticals (2) · Ionis Pharmaceuticals, Inc. (2) · Novartis Pharmaceuticals (2) · CRISPR Therapeutics AG (1) · DongKoo Bio & Pharma (1) · Eli Lilly and Company (1) · Elif Oral (1) · GeneCradle Inc (1) · GlaxoSmithKline (1) · Ikaria Bioscience Pty Ltd (1) · Korea United Pharm. Inc. (1) · Kylonova (Xiamen) Biopharma co., LTD. (1) · Marea Therapeutics (1)
United States (20) · Canada (8) · Australia (6) · China (5) · United Kingdom (4) · New Zealand (3) · South Korea (2) · France (1) · Netherlands (1) · Singapore (1) · South Africa (1)
Michael H Davidson, MD, FACC (2) · Alan K Copa, PharmD (1) · Alan K. Copa, Pharm. D. (1) · Alex DePaoli (1) · Andrea L Lawless, MD (1) · Brad West, ND (1) · Elif A Oral, M.D. (1) · Eric Chen, MD (1) · Gregory C Shearer, PhD (1) · Injin Jang, Dr. (1)
PMID 21252253, PMID 25393536, PMID 25889044, PMID 28391875, PMID 28538111, PMID 28538136, PMID 31242752, PMID 31329855, PMID 32473640, PMID 33900278, PMID 34431493, PMID 37626170, PMID 38320498, PMID 40383129, PMID 41946917
2015 (1), 2025 (1)